Literature DB >> 27377533

Plasma IFN-γ and IL-6 levels correlate with peripheral T-cell numbers but not toxicity in RCC patients treated with CAR T-cells.

Yarne Klaver1, Sabine C L van Steenbergen1, Stefan Sleijfer2, Reno Debets1, Cor H J Lamers3.   

Abstract

Autologous T-cells genetically modified to express a chimeric antigen receptor (CAR) against carboxy-anhydrase-IX (CAIX) were administered to twelve patients with CAIX-positive metastatic renal cell carcinoma. Here, we questioned whether plasma cytokine levels following treatment or in vitro cytokine production from the T-cell infusion products could serve as predictors for peripheral T-cell persistence or in vivo T-cell activity. We demonstrated that CAR surface as well as gene expression are down-regulated following T-cell infusion, and that peripheral numbers of CAR T-cells are best captured by flow cytometry and not by qPCR. Numbers of CAR T-cells in blood correlated with plasma levels of IFN-γ and IL-6, but not with any of the other cytokines tested. Plasma IFN-γ or IL-6 levels did not correlate with liver enzyme values. Thus, out of 27 cytokines tested, IFN-γ and IL-6 levels in plasma are potential surrogate markers for CAR T-cell persistence in solid tumors.
Copyright © 2016. Published by Elsevier Inc.

Entities:  

Keywords:  Chimeric antigen receptor; Cytokines; IFN-γ; Immune monitoring; Renal cell cancer; T-cell

Mesh:

Substances:

Year:  2016        PMID: 27377533     DOI: 10.1016/j.clim.2016.06.014

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  5 in total

1.  Targeting hypoxia downstream signaling protein, CAIX, for CAR T-cell therapy against glioblastoma.

Authors:  Jing Cui; Qi Zhang; Qi Song; Herui Wang; Pauline Dmitriev; Mitchell Y Sun; Xiaoyu Cao; Yang Wang; Liemei Guo; Iris H Indig; Jared S Rosenblum; Chunxia Ji; Dongqing Cao; Kaiyong Yang; Mark R Gilbert; Yu Yao; Zhengping Zhuang
Journal:  Neuro Oncol       Date:  2019-11-04       Impact factor: 12.300

2.  T Cell Maturation Stage Prior to and During GMP Processing Informs on CAR T Cell Expansion in Patients.

Authors:  Yarne Klaver; Sabine C L van Steenbergen; Stefan Sleijfer; Reno Debets; Cor H J Lamers
Journal:  Front Immunol       Date:  2016-12-26       Impact factor: 7.561

Review 3.  Genetically enhanced T lymphocytes and the intensive care unit.

Authors:  Tiberiu Tat; Huming Li; Catalin-Sorin Constantinescu; Anca Onaciu; Sergiu Chira; Ciprian Osan; Sergiu Pasca; Bobe Petrushev; Vlad Moisoiu; Wilhelm-Thomas Micu; Cristian Berce; Sebastian Tranca; Delia Dima; Ioana Berindan-Neagoe; Jianliang Shen; Ciprian Tomuleasa; Liren Qian
Journal:  Oncotarget       Date:  2018-03-27

Review 4.  Inflammatory Biomarkers as Predictors of Response to Immunotherapy in Urological Tumors.

Authors:  Giuseppe Schepisi; Nicole Brighi; Maria Concetta Cursano; Giorgia Gurioli; Giorgia Ravaglia; Amelia Altavilla; Salvatore Luca Burgio; Sara Testoni; Cecilia Menna; Alberto Farolfi; Chiara Casadei; Giuseppe Tonini; Daniele Santini; Ugo De Giorgi
Journal:  J Oncol       Date:  2019-09-19       Impact factor: 4.375

Review 5.  The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection.

Authors:  Ana Copaescu; Olivia Smibert; Andrew Gibson; Elizabeth J Phillips; Jason A Trubiano
Journal:  J Allergy Clin Immunol       Date:  2020-09       Impact factor: 10.793

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.